<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NATALIZUMAB</span><br/>(na-tal'-i-zu-mab)<br/><span class="topboxtradename">Tysabri<br/></span><b>Classifications:</b> <span class="classification"> biologic response modifier</span>; <span class="classification">monoclonal antibody</span><br/><b>Prototype: </b>Basiliximab<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>300 mg/15 mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Natalizumab is a recombinant immunoglobulin-G4 (IgG4) monoclonal antibody thought to interfere with the migration of lymphocytes
         and monocytes into the CNS endothelium of patients with multiple sclerosis, thereby reducing inflammation and demyelination
         of CNS white matter.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibition of T-cell infiltration into the brain is thought to impede the demyelinating process of multiple sclerosis. Natalizumab
         is also thought to attenuate T-lymphocytemediated intestinal inflammation in Crohn's disease and possibly ulcerative
         colitis.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of relapsing forms of multiple sclerosis.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of Crohn's disease.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Safety and efficacy of the drug have not been established for chronic progressive multiple sclerosis. Prior hypersensitivity
         to natalizumab; murine protein hypersensitivity; active infection; lactation; females of childbearing age; pregnancy (category
         C); children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Coadministration with other immunosuppressive medication; diabetes mellitus, immunocompromised patients; exposure to infection
         or tuberculosis.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Multiple Sclerosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 300 mg infused over 1 h every 4 wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Before and after dilution, solution should be colorless and clear to slightly opaque. Do not use if the solution has visible
                  particles, flakes, color, or is cloudy. Withdraw 15 mL from the vial and add to an IV bag with 100 mL of NS. Do not use with
                  any other diluent. Gently invert the bag to mix; do not shake. The IV solution must be used within 8 h.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Flush IV line before/after with NS. Infuse over 1 h. Do not give a bolus dose. Stop infusion immediately if S&amp;S of hypersensitivity
                  appear.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive/Y-site:</span> Do not mix or infuse with other drugs. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store IV solution for up to 8 h at 2°8° C (36°46° F). Allow solution to warm to room temperature
            before administration
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-life">Anaphylaxis</span> (rare, usually within 2 h of infusion), infections, fatigue, rigors. <span class="typehead">CNS<b></b> 			:</span> Depression, headache, syncope, tremor. <span class="typehead">CV<b></b> 			:</span> Chest discomfort. <span class="typehead">GI<b></b> 			:</span> Abdominal discomfort, abnormal liver function tests. <span class="typehead">Hematologic<b></b> 			:</span> Local bleeding from infusion site. <span class="typehead">Musculoskeletal<b></b> 			:</span> Arthralgia. <span class="typehead">Respiratory<b></b> 			:</span> Pneumonia. <span class="typehead">Skin<b></b> 			:</span> Acute urticaria. <span class="typehead">Urogenital<b></b> 			:</span> Urinary frequency, irregular menstruation, amenorrhea, dysmenorrhea. <span class="typehead"> Other<b></b> 			:</span> Infusion-related reactions (headache, dizziness, fatigue, hypersensitivity reactions, urticaria, pruritus, and rigors). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug<b></b> 			:</span> May reduce the effectiveness of <span class="classification">vaccines</span> and <span class="classification">toxoids</span>; may increase risk of infection with <span class="classification">immunosuppressants</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Half-Life:</span> 11 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>During IV infusion and for 12 h after, monitor closely for S&amp;S of hypersensitivity (e.g., urticaria, dizziness, fever,
            rash, chills, pruritus, nausea, flushing, hypotension, dyspnea, and chest pain).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report immediately any of the following during/after IV infusion: difficulty breathing, wheezing or shortness of breath, swelling
            or tightness about the neck and throat, chest pain, skin rash or hives.
         </li>
<li>Report promptly S&amp;S of infection (e.g., cough, fever, chills, or sore throat).</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>